Future Diagnostics
Future Diagnostics is a Netherlands-based CDMO founded in 1997 that provides end-to-end IVD immunoassay development, validation, and small-to-medium scale manufacturing services to biotech, pharmaceutical, and diagnostic companies worldwide, differentiated by its proprietary micro-SCY™ antibody screening platform.
- Company typePrivate
- Founded1997
- HeadquartersWijchen, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Future Diagnostics does
Future Diagnostic Solutions B.V. (operating as Future Diagnostics or FDX) is a Netherlands-based contract development and manufacturing organization (CDMO) founded in 1997 and headquartered in Wijchen. The company delivers end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharmaceutical, and diagnostic companies worldwide. Its service portfolio spans the full development lifecycle — proof-of-concept, feasibility, design, optimization, verification, validation, pilot production, and tech transfer — across immunoassay formats including ELISA, chemiluminescence (CLIA), fluorescence (FIA), multiplex microarray, point-of-care, and turbidimetric immunoassays. Beyond development, Future Diagnostics operates a CDMO manufacturing arm offering bead coating, bioconjugation, lyophilization (including Accusphere technology), and contract manufacturing within an ISO 13485-certified facility. A key technical differentiator is the proprietary micro-SCY™ antibody screening platform, which the company claims delivers faster convergence on optimal antibody-antigen matches and reduced trial-and-error in assay development. The company also operates on-site automated clinical analyzers (Abbott Architect, Abbott Alinity, Beckman Coulter DxI 600) for comparison studies and method validation.
The business model is project-based professional services delivered through Statements of Work (SOW) with milestone-based payments, paired with managed-services contract manufacturing. Pricing is not publicly disclosed; each project is scoped individually, and compensation is indexed to supplier tariffs, wages, taxes, transport costs, and other surcharges, with annual price adjustments. The company's standard liability cap is €250,000 per SOW, and contracts are typically multi-year. GTM motion is sales-led and direct B2B, targeting three primary vertical segments: diagnostic companies, pharmaceutical companies (with a dedicated Biomarkers & Pharma-Related IVDs offering focused on companion diagnostics), and biotech companies. The company markets itself through technical blog content, peer-reviewed publications and posters (including a 2024 micro-SCY™ poster), case studies, and industry event participation. Quality systems are embedded across the offering: ISO 13485 registration, IVDR compliance, FDA QSR compliance, and GDPR-compliant data handling. The company claims 25+ years of specialized IVD immunoassay expertise (also stated as 28 years elsewhere), hundreds of successful assays delivered worldwide, and named-customer relationships with global multinationals including Abbott, Beckman Coulter, BioMérieux, Bio-Rad, Siemens Healthineers, Philips, Canon Medical Systems, Ortho-Clinical Diagnostics, Volition, and Tecan. Leadership includes Frank B. Martel (Managing Director) and Ernst Lindhout (Head of Research and Science).
Future Diagnostics firmographics
Firmographics- Name
- Future Diagnostics
- Legal name
- Future Diagnostic Solutions B.V.
- Website
- https://future-diagnostics.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Future Diagnostics is a Netherlands-based CDMO founded in 1997 that provides end-to-end IVD immunoassay development, validation, and small-to-medium scale manufacturing services to biotech, pharmaceutical, and diagnostic companies worldwide, differentiated by its proprietary micro-SCY™ antibody screening platform.
- Ownership category
- akta.pro rank
Future Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics Contract Development & Manufacturing
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where Future Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Wijchen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Future Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Contract IVD Assay Development Services: Project-based professional services for IVD assay development, covering proof-of-concept, feasibility, design, verification, validation, and tech transfer phases. Revenue is generated through Statement of Work (SOW) agreements with milestone-based payments. Services include custom assay development, optimization of existing assays, and verification & validation studies.
- CDMO Manufacturing Services: Contract manufacturing and reagent services including bead coating, conjugation, lyophilization, and micro-SCY services. Small to medium scale manufacturing for assay components and finished products. Revenue generated through manufacturing agreements with clients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing based on scope, timeline, and complexity |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Future Diagnostics product offering
Product offeringCore offering
Future Diagnostics (FDX) is a Contract Development and Manufacturing Organization (CDMO) delivering end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharma, and diagnostic companies. Its portfolio spans immunoassay development (ELISA, FIA, CLIA, microarray, turbidimetric), point-of-care tests, automated immunoassay analyzers, verification & validation, IVDR performance evaluation studies, and small-to-medium scale ISO 13485 contract manufacturing including bead coating, conjugation, and lyophilization. The proprietary micro-SCY™ platform provides differentiated antibody screening capabilities to accelerate assay development.
Product overview
Future Diagnostics (FDX) is a CDMO (Contract Development and Manufacturing Organization) offering end-to-end IVD assay development services, not a software product company. Its portfolio is organized into two main divisions: IVD Assay Development Services and CDMO Manufacturing Services. The IVD services span assay types including ELISA/immunoassays, multiplex microarrays, point-of-care tests, and automated immunoassay analyzers — all supported by verification & validation, performance evaluation studies (IVDR), and comparison studies on automated platforms. The CDMO arm covers contract manufacturing and reagent services (bead coating, conjugation, lyophilization). A key differentiator is the proprietary micro-SCY™ platform for accelerated antibody screening. FDX serves biotech, pharma, and diagnostic companies from proof-of-concept through commercialization, with in-house ISO 13485 and FDA-registered manufacturing capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- micro-SCY™: Proprietary antibody screening platform for unmatched antibody screening insights, delivering faster convergence on optimal antibody-antigen matches and reduced trial-and-error
Products and services
- IVD Assay Development Services
Quantifiable outcome
- Hundreds of successful assays delivered worldwide
- +1 more outcomes
Companies that use Future Diagnostics
Customer profileNamed customers16 records
Segments3 records
Ideal customer profiles2 records
Future Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Future Diagnostics partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Future Diagnostics competitors and assessment
Company assessmentDirect peers
- Mercodia: Mercodia is a Swedish CDMO specializing in IVD immunoassay development and manufacturing, with deep expertise in ELISA and clinical immunoassays. It is the closest direct peer to Future Diagnostics in terms of service model, customer base (pharma and diagnostic companies), and technology focus.
- Surmodics: Surmodics provides IVD contract manufacturing and reagent components, including bio-conjugation, antibody stabilization, and assay components. It overlaps directly with Future Diagnostics' CDMO services in bead coating, conjugation, and lyophilization.
- Bio-Techne: Bio-Techne manufactures proteins, antibodies, and immunoassay development reagents serving the diagnostics and life sciences markets. It is comparable to Future Diagnostics' biomarker assay and reagent development services for biotech and pharma customers.
- Meridian Bioscience: Meridian Bioscience develops, manufactures, and markets diagnostic test kits and reagents for infectious disease and other conditions. It competes in IVD assay development and manufacturing for similar clinical diagnostic customers.
Broad incumbents
- Eurofins Scientific: Eurofins is a global contract testing and CDMO network with significant IVD and life sciences testing services. While broader in scope than Future Diagnostics, it competes for similar biotech and diagnostic validation work and has much greater scale.
- Charles River Laboratories: Charles River provides CDMO and CRO services across biologics, diagnostics, and life sciences research. It overlaps with Future Diagnostics in assay development and contract manufacturing for diagnostic and pharma clients.
- DiaSorin: DiaSorin is an Italian IVD company that develops and manufactures immunoassay kits and automated platforms. It is a larger, vertically integrated peer in IVD assay development for clinical diagnostics.
- Thermo Fisher Scientific: Thermo Fisher operates one of the largest life sciences CDMO and IVD reagent businesses globally. While far broader than Future Diagnostics, it competes for similar biotech and pharma assay development projects.
- Agilent Technologies: Agilent provides analytical instruments, reagents, and contract laboratory services for life sciences and diagnostics. Its diagnostics and clinical market business overlaps with Future Diagnostics' IVD development services.
Emerging players
- Quanterix: Quanterix develops ultra-sensitive single-molecule immunoassay technology and contract research services. It overlaps with Future Diagnostics in advanced immunoassay development, though with a more specialized platform focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Future Diagnostics social profiles
Digital presenceFuture Diagnostics compliance and trust
Trust signalCompliance4 records
Future Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Future Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Future Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Future Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Future Diagnostics
What does Future Diagnostics do?
Future Diagnostics (FDX) is a Contract Development and Manufacturing Organization (CDMO) delivering end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharma, and diagnostic companies. Its portfolio spans immunoassay development (ELISA, FIA, CLIA, microarray, turbidimetric), point-of-care tests, automated immunoassay analyzers, verification & validation, IVDR performance evaluation studies, and small-to-medium scale ISO 13485 contract manufacturing including bead coating, conjugation, and lyophilization. The proprietary micro-SCY™ platform provides differentiated antibody screening capabilities to accelerate assay development.
Is Future Diagnostics a public or private company?
Future Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Future Diagnostics founded?
Future Diagnostics was founded in 1997. It employs 101 to 250 people.
Where is Future Diagnostics based?
Future Diagnostics is headquartered in Wijchen, Netherlands, in the Europe region.
How does Future Diagnostics make money?
Two revenue lines are on record. Contract IVD Assay Development Services are the primary driver. The others are CDMO Manufacturing Services.
Who are Future Diagnostics's main competitors?
Direct peers on record are Mercodia, Surmodics, Bio-Techne and Meridian Bioscience. Broad incumbents are Eurofins Scientific, Charles River Laboratories, DiaSorin, Thermo Fisher Scientific and Agilent Technologies. Quanterix is listed as an emerging player.
Does Future Diagnostics have an API?
No public API is recorded for Future Diagnostics.
What industry is Future Diagnostics in?
Future Diagnostics's product category is In Vitro Diagnostics Contract Development & Manufacturing. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.